ACEPODIA

Live / Registered — Registered (as of 10 Feb 2026)

What this means for you

Registered since 10 Feb 2026. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
98044259
Registration number
8137873
Mark type
Stylized text
Filed
15 Jun 2023
Published for opposition
16 Apr 2024
Registered
10 Feb 2026
Attorney of record
Evan R. Witt

Goods and services

  • Class 005 — Pharmaceuticals: Biological preparations for use in cell cultures for medical or therapeutic purposes; Biological tissue cultures for medical purposes; Medicinal preparations for the treatment and prevention of cancer, tumors, autoimmune disease, neuronal disease, hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases for human purposes; Drugs, namely, pharmaceuticals for the treatment and prevention of cancer, tumors, autoimmune disease, neuronal disease, hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases for medical purposes; Pharmaceutical preparations for the treatment and prevention of cancer, tumors, autoimmune disease, neuronal disease, hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases; Cells for clinical, medical, veterinary, or therapeutic purposes or use; Cell-derived preparations, namely, natural killer cell, gamma delta T cell, or other immune cell-derived preparations, for clinical, medical, veterinary, or therapeutic purposes; Therapeutic products derived from cells or cell-derived preparations, namely, natural killer cells, gamma delta T cell, and other immune cell, for clinical, medical, veterinary, or therapeutic purposes; Kits comprised of cells and reagents and also containing related instructions for clinical, medicinal, veterinary, or therapeutic purposes or use; Kits comprised of cell-derived preparations, namely, natural killer cell, gamma delta T cell, and other immune cell-derived preparations and reagents and also containing related instructions, for clinical, medicinal, veterinary, or therapeutic purposes or use; Pharmaceutical preparations, pharmaceutical products, therapeutic agents, and pharmaceuticals for targeting tissues based on select tissue markers and ligands, or for the purpose of binding ligands using engineered proteins and receptors; Pharmaceuticals, namely, pharmaceutical preparations, pharmaceutical products, therapeutic agents, and pharmaceuticals for use in the prevention and treatment of cancer, tumors, hematologic disease, solid cancers, hyperproliferative disease, autoimmune disease, neuronal diseases, hematopoietic cell-related diseases, metabolic syndrome, infectious diseases, immune disease or disorder, and inflammation and inflammatory diseases and in cellular transplants; Biotechnology and pharmaceutical products, namely, therapeutic cells, therapeutic peptide, therapeutic proteins, and therapeutic nucleic acids for human use for the treatment and prevention of cancer, tumors, autoimmune disease, a neuronal disease, a hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases; Pharmaceutical preparations or pharmaceutical products, namely, cell media for use in activating t-cells for use in adoptive t-cell therapy for the treatment of hematological and solid cancers; Pharmaceutical preparations, biological preparations, and therapeutic agents to modulate cell function or cell fate; Biological preparations and therapeutic agents used for medical cell therapy, adoptive immunotherapy, or other immunotherapy; Therapeutic cell preparation based on NK cells (natural killer cells), gamma delta T cell, other immune cell, or other cell for the treatment of cancer, tumors, neuronal diseases, hematopoietic cell-related diseases, metabolic syndrome, infectious diseases, auto-immune diseases, and inflammatory and immune disorders; Bio-engineered component for a therapeutic material, namely, cell lines based on NK cells (natural killer cells), gamma delta T cell, or other immune cell used for medical or clinical use used for immunotherapy

Owner

Prosecution history

  • 10 Feb 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
  • 10 Feb 2026 — REGISTERED-PRINCIPAL REGISTER
  • 21 Jan 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
  • 21 Jan 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
  • 29 Dec 2025 — STATEMENT OF USE PROCESSING COMPLETE
  • 10 Jun 2025 — USE AMENDMENT FILED
  • 04 Dec 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
  • 10 Jun 2025 — TEAS STATEMENT OF USE RECEIVED
  • 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 26 Nov 2024 — SOU EXTENSION 1 GRANTED
  • 26 Nov 2024 — SOU EXTENSION 1 FILED
  • 26 Nov 2024 — SOU TEAS EXTENSION RECEIVED
  • 11 Jun 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 16 Apr 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 16 Apr 2024 — PUBLISHED FOR OPPOSITION

View this trademark record on Marksy